Tourmaline Bio, Inc. (TRML) Research

Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED). Established in 2021, this enterprise is headquartered in New York, New York.

Market snapshot

Symbol
TRML
Price
$47.98
Day change
0.00%
Market cap
$1.2B
P/E ratio
-18.09x
52-week range
11.56-48.27
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$48.50

Peer companies

  • Amylyx Pharmaceuticals, Inc. (AMLX)
  • Dianthus Therapeutics, Inc. (DNTH)
  • Enliven Therapeutics, Inc. (ELVN)
  • Immatics N.V. (IMTX)
  • ORIC Pharmaceuticals, Inc. (ORIC)
  • Precigen, Inc. (PGEN)
  • Relay Therapeutics, Inc. (RLAY)
  • Syndax Pharmaceuticals, Inc. (SNDX)

Recent insider activity

  • SIEGALL CLAY B — D-Return (15000 shares) on 2025-10-28
  • SIEGALL CLAY B — D-Return (16800 shares) on 2025-10-28
  • SIEGALL CLAY B — D-Return (20000 shares) on 2025-10-28
  • Thiara Parvinder — D-Return (16800 shares) on 2025-10-28
  • Thiara Parvinder — U-Tender (83782 shares) on 2025-10-28

Open Tourmaline Bio, Inc. (TRML) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.